US businesses are expected to sell the COVID-19 vaccine for $ 50-60 per dose

Biotechnology company Moderna said it was expected that a course of their COVID-19 vaccine would cost around US $ 50-60, but prices could vary depending on the course of the disease. 

Biotechnology Company Moderna said it was expected that a course of their COVID-19 vaccine would cost around US $ 50-60, but prices could vary depending on the course of the disease.

According to the latest information on Sputnik News, a course of COVID-19 vaccine is expected to cost about $ 50-60 USD, this is the latest report from US biotechnology company Moderna.

The company also explained that this is the price the company expects to set for the US and other countries with "high income levels".

However, the company also confirmed that prices may vary depending on the course of the disease.

Previously, companies Pfizer and BioNTech announced their vaccine prices were cheaper, having just signed an agreement with the US government to sell up to 600 million doses of COVID-19 vaccine at a cost of $ 19.5 per dose.

It was previously reported that US biotechnology company Moderna had begun the third phase of clinical trials of a vaccine to prevent COVID-19.

The company's vaccine production project is funded by the US government with nearly $ 500 million in funding and is allowed to deploy human-scale vaccines on a large scale.

"The virus has been rapidly removed from vaccinated animals." 

said Dr. Barney S. Graham, deputy director of the National Center for Research on Vaccines at the National Institute of Allergy and Infectious Diseases.

According to National Geographic, the mRNA-1273 vaccine entering the third phase of testing is not unusual, given the fact that Moderna has not completed the second phase of the trial starting in late May.

"This method will help scientists to make the vaccine faster, the mRNA vaccine can be ready for testing in a few hours or days. Of course it's in theory."

Chairman of a committee of the Association International vaccines - Mrs. Margaret Liu expressed her opinion.